![](https://www.ctvnews.ca/polopoly_fs/1.6968646.1721316302!/httpImage/image.jpg_gen/derivatives/landscape_800/image.jpg)
BREAKING High-profile Liberal minister quitting cabinet, not running in next election
Labour Minister Seamus O'Regan has announced he will not run in the next federal election, and will be quitting his cabinet position Friday.
Drugmaker Merck asked U.S. regulators Monday to authorize its pill for treating COVID-19 in what would add an entirely new and easy-to-use weapon to the world's arsenal against the pandemic.
If cleared by the Food and Drug Administration -- a decision that could come in a matter of weeks -- it would be the first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.
An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on U.S. hospitals and helping to curb outbreaks in poorer countries with weak health care systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.
The FDA will scrutinize company data on the safety and effectiveness of the drug, molnupiravir, before rendering a decision.
Merck and its partner Ridgeback Biotherapeutic said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. That is roughly the way COVID-19 infusion drugs are used.
"The value here is that it's a pill so you don't have to deal with the infusion centres and all the factors around that," said Dr. Nicholas Kartsonis, a senior vice president with Merck's infectious disease unit. "I think it's a very powerful tool to add to the toolbox."
The company reported earlier this month that the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19. The results were so strong that independent medical experts monitoring the trial recommended stopping it early.
Side effects were similar between patients who got the drug and those in a testing group who received a dummy pill. But Merck has not publicly detailed the types of problems reported, which will be a key part of the FDA's review.
Top U.S. health officials continue to push vaccinations as the best way to protect against COVID-19.
"It's much, much better to prevent yourself from getting infected than to have to treat an infection," Dr. Anthony Fauci said while discussing Merck's drug last week.
Still, some 68 million eligible Americans remain unvaccinated, underscoring the need for effective drugs to control future waves of infection.
The prospect of a COVID-19 pill comes amid other encouraging signs: New cases per day in the U.S. have dropped below 100,000 on average for the first time in over two months, and deaths are running at about 1,700 a day, down from more than 2,000 three weeks ago.
Also, the average number of vaccinations dispensed per day has climbed past 1 million, an increase of more than 50% over the past two weeks, driven by the introduction of booster shots and workplace vaccine requirements.
Still, heath authorities are bracing for another possible surge as cold weather drives more people indoors.
Since the beginning of the pandemic, health experts have stressed the need for a convenient pill. The goal is for something similar to Tamiflu, the 20-year-old flu medication that shortens the illness by a day or two and blunts the severity of symptoms like fever, cough and stuffy nose.
Three FDA-authorized antibody drugs have proved highly effective at reducing COVID-19 deaths, but they are expensive, hard to produce and require specialty equipment and health professionals to deliver.
Assuming FDA authorization, the U.S. government has agreed to buy enough of the pills to treat 1.7 million people, at a price of roughly US$700 for each course of treatment. That's less than half the price of the antibody drugs purchased by the U.S. government -- over $2,000 per infusion -- but still more expensive than many antiviral pills for other conditions.
Merck's Kartsonis said in an interview that the $700 figure does not represent the final price for the medication.
"We set that price before we had any data, so that's just one contract," Kartsonis said. "Obviously we're going to be responsible about this and make this drug as accessible to as many people around the world as we can."
Kenilworth, New Jersey-based Merck has said it is in purchase talks with governments around the world and will use a sliding price scale based on each country's economic means. Also, the company has signed licensing deals with several Indian generic drugmakers to produce low-cost versions of the drug for lower-income countries.
Several other companies, including Pfizer and Roche, are studying similar drugs and are expected to report results in the coming weeks and months. AstraZeneca is also seeking FDA authorization for a long-acting antibody drug intended to provide months of protection for patients who have immune-system disorders and do not adequately respond to vaccination.
Some experts predict various COVID-19 therapies eventually will be prescribed in combination to better protect against the worst effects of the virus.
------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content
Labour Minister Seamus O'Regan has announced he will not run in the next federal election, and will be quitting his cabinet position Friday.
Its authors call it the U.S. conservative movement's 'mandate for leadership,' designed to guide a potential second term for former U.S. president Donald Trump.
A B.C. woman has been ordered to repay her ex for a ticket to Coldplay's 2023 concert in Vancouver – in a small claims decision that highlights the distinction between gifts and loans under Canadian law.
Researchers say they know the 'Big One' is coming, but when should we expect it? Scientists say predicting when a megathrust earthquake will occur is a guessing game.
All the major Canadian grocers are now on board for a grocery code of conduct, paving the way for industry guidelines that have been several years in the making.
Former president Barack Obama has privately expressed concerns to Democrats about President Joe Biden’s candidacy, and Speaker Emerita Nancy Pelosi privately warned Biden that Democrats could lose the ability to seize control in the House if he didn’t step away from the race.
RCMP say a one person was killed and eight others were injured when a bus and an SUV collided head-on in southern Alberta on Wednesday.
Rare images of the Mashco Piro, an uncontacted Indigenous tribe in the remote Peruvian Amazon, were published on Tuesday by Survival International,
In the last few weeks, there has been a surge in the number of Americans searching online about moving to Canada and recent political events appear to have been a major catalyst.
A donated clawfoot bathtub has become the preferred lounging spot for a pair of B.C. grizzly bears, who have been taking turns relaxing and reclining in it – with minimal sibling squabbling – for the past year.
A pair of cemetery investigators are cleaning and preserving as many gravestones they have permission to work on, as they conduct their research and document gravestones.
After more than three years, a B.C. woman has been reunited with a lost family heirloom.
One of Edmonton’s main contributors to Google Street View is a man who dresses up as an alien.
Nearly 10 years after it was first proposed, an interactive piece of public art is officially open in Vancouver's Hastings Park.
An event July 22 at Dynamic Earth in Sudbury will mark the 60th anniversary of the iconic Big Nickel, the largest coin in the world.
Cyclist Jagjeet Singh cruised through Montreal on Sunday morning as he rides across the country to raise money for a children's charity.
A rare ammonite fossil – about 75 million years old - has been discovered in eastern Saskatchewan.
Seven-year-old goalie Hudson Hardill is an unlikely Calgary Flames fan, being that he lives in Peterborough, Ont., and his dad Chris is a Toronto Maple Leafs fan.